New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 5, 2014
11:17 EDTQCOR, GDP, CONN, CIEN, KKD, BIG, DLLR, OVTI, GES, INCYOptions with decreasing implied volatility
Options with decreasing implied volatility: DLLR CONN INCY BIG GDP GES KKD QCOR OVTI CIEN
News For DLLR;CONN;INCY;BIG;GDP;GES;KKD;QCOR;OVTI;CIEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 9, 2014
14:57 EDTCIENTelecom equipment stocks rally after Verizon CFO comments on wireless CapEx
Telecom equipment stocks, which opened lower, rallied after Verizon (VZ) CFO Fran Shammo said he sees wireless CapEx continuing to trend upward. Shammo, speaking at the UBS 42nd Annual Global Media And Communications Conference, said, "The day we start to cut wireless CapEx is the day we start to wonder where the future of this industry is going." Ciena (CIEN), JDSU (JDSU), and Finisar (FNSR) all reversed earlier losses. PRICE ACTION: In afternoon trading, Ciena is up 1.5%, JDS Uniphase is up 3.8%, and Finisar is up 4.5%. Verizon, which was downgraded this morning to Neutral from Buy by RW Baird, is trading down almost 5%.
12:37 EDTCONNConn's downgraded to Hold from Buy at Canaccord
Canaccord downgraded Conn's to Hold following the Q3 report citing credit deterioration and limited visibility. Price target is $21.
12:25 EDTCONNOn The Fly: Midday Wrap
Subscribe for More Information
10:19 EDTCONNHigh option volume stocks
Subscribe for More Information
10:08 EDTCONNHigh option volume stocks
Subscribe for More Information
09:21 EDTCONNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: AutoZone (AZO), up 3.8%... Burlington Stores (BURL), up 3.3%. ALSO HIGHER: bluebird bio (BLUE), up 56.5% after price target raised at Piper Jaffray and SunTrust... Camtek (CAMT), up 6.7% after being awarded a $2.8M order from a semiconductor manufacturer... PDC Energy (PDCE), up 5.8% after providing fiscal 2015 production guidance... Mast Therapeutics (MSTX), up 3.1% after reporting that it will begin recruiting patients for MST-188 study in first half of fiscal 2015... Idera Pharmaceuticals (IDRA), up 1.4% after announcing data for its lead product candidate, IMO-8400. DOWN AFTER EARNINGS: UTi Worldwide (UTIW), down 10.8%... CONN'S (CONN), down 35.9% after reporting third quarter results, withdrawing fiscal 2015 guidance, stating that there is no timetable set for completion of strategic alternatives, and announcing the departure of its CFO. ALSO LOWER: Apple (AAPL), down 1.6% after Pacific Crest says that weak iPad demand could cause Apple to miss estimates and following a Wall Street Journal report that a judge denied Apple's efforts to throw out iPod pricing lawsuit... Allied Nevada Gold (ANV), down 30.1% after announcing pricing of common stock and warrant offering... United Continental (UAL), down 2.7% after reporting November traffic.
09:03 EDTKKDKrispy Kreme December volatility elevated as shares trend up into Q3 and outlook
Krispy Kreme December call option implied volatility is at 74, January is at 46, February is at 41; compared to its 26-week average of 42 according to Track Data, suggesting large near term price movement into the expected release of Q3 results today.
07:41 EDTGDPGoodrich Petroleum liquidity concerns overblown, says SunTrust
Subscribe for More Information
07:11 EDTINCYEli Lilly and Incyte announce Phase 3 RA-BEACON study met primary endpoint
Subscribe for More Information
07:09 EDTCONNConn's announces departure of CFO Brian Taylor
Connís announced the departure of Brian Taylor, the companyís CFO. Effective immediately, the company has appointed Mark Haley as Interim CFO. Prior to joining Connís as VP and Chief Accounting Officer in October 2014, Haley was Vice President and Chief Accounting Officer at Coldwater Creek, Inc. for four years. The company has engaged an executive search firm to identify qualified candidates for the permanent CFO position. The search process will include both internal and external candidates.
07:05 EDTCONNConn's sees Q4 SSS flat to up 3%
The following are the companyís expectations for its business for the fourth quarter: Same stores sales flat to up 3%; Retail gross margin between 39.0% and 40.0%; Opening of 2 new stores during the quarter; and Closure of 1 store during the quarter. Beginning with December results, the company will release, shortly after the end of the month, same store sales and greater than 60 days delinquency performance. The company believes this will provide investors with timely, relevant information about business trends and expects to continue this practice until the company experiences more stability in its results.
07:04 EDTCONNConn's withdraws FY15 guidance
Subscribe for More Information
07:04 EDTCONNConn's says no timetable set for completion of strategic alternatives process
In October, the Company announced that its Board of Directors authorized management to explore a full range of strategic alternatives for the Company to potentially enhance value for stockholders. The Company has engaged an independent financial advisor to assist in this process and is actively engaged in preliminary discussions with multiple parties about a range of potential strategic alternatives. No timetable has been set for the completion of the process. Conn's does not expect to comment further or update the market with any further information on the process unless and until its Board of Directors has approved a specific transaction or otherwise deems disclosure appropriate or necessary. There can be no assurance that this strategic alternatives review will result in the Company changing its current business plan, pursuing a particular transaction or completing any such transaction.
07:03 EDTCONNConn's says initiating search for president
Subscribe for More Information
07:03 EDTCONNConn's reports Q3 EPS (8c), may not compare to consensus 68c
Subscribe for More Information
06:10 EDTGDPGoodrich Petroleum implied volatility of 205 at upper end of index mean range
December 8, 2014
13:07 EDTINCYNovartis announces data from Jakavi trial
Novartis (NVS) announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi, supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively. In an analysis of 1,144 patients treated with Jakavi to date in this ongoing expanded access study, 69% of patients achieved >50% reduction in spleen size from baseline and patients also experienced a clinically meaningful improvement in myelofibrosis symptom score, important treatment goals for patients with myelofibrosis. Findings from the study were presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, California. Novartis research and development efforts, in collaboration with Incyte Corporation (INCY), include early-phase and post-marketing studies in myelofibrosis and other myeloproliferative neoplasms. More than 50 abstracts on ruxolitinib are being presented at ASH, including three oral presentations exploring combinations of ruxolitinib with various investigational compounds, evaluating the possibility of simultaneously targeting multiple cancer pathways that may be involved in the pathogenesis of myelofibrosis. The JUMP study is a Phase IIIb, expanded-access trial for countries with no access to Jakavi outside of a clinical trial. The open-label, multicenter study analyzed 1,144 enrolled myelofibrosis patients who received daily starting doses of either 5 mg, 15 mg or 20 mg of Jakavi twice daily based on platelet counts at baseline. The primary endpoint is assessment of safety and tolerability of Jakavi. Overall, the safety and efficacy profile of Jakavi was consistent with previous studies.
09:34 EDTGDPGoodrich Petroleum downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
09:14 EDTCIEN Ciena volatility increase into Q4 and outlook
Subscribe for More Information
08:26 EDTBIGBig Lots sell-off unwarranted at FBR Capital
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use